Melissa Alsina, MD
Hematology · Tampa, FLNPI 1184656746
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,567 of the $63,885 with a category attached, or 74.5%. 14 manufacturers reported payments, led by Bristol Myers Squibb at 29.9% of the total. Reporting peaked in 2019 at $17,004 and has fallen 71.7% since, to $4,815 in 2025.
Across 73 payments — averaging $875.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$19K
- Johnson & Johnson$14K
- Legend Biotech USA Inc.$9K
- GSK$6K
- Sanofi$6K
- Janssen Global Services, LLC$4K
- plus $6K from 8 others
Across 161 payments — averaging $80,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$5M
- Amgen$4.2M
- Pfizer$2.6M
- Janssen Research & Development, LLC$736K
- AstraZeneca$347K
- E.r. Squibb & Sons, L.L.C.$98K
What the payments were for
- Consulting fees$47,56774%
- Speaking & faculty fees$10,60017%
- Travel & lodging$2,3234%
- Food & beverage$3,3955%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 17 | $19,122 |
| Johnson & Johnson(2 entities) | 24 | $14,057 |
| Legend Biotech USA Inc. | 5 | $8,632 |
| GSK | 3 | $6,431 |
| Sanofi | 8 | $5,711 |
| Janssen Global Services, LLC | 2 | $4,200 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,095 |
| Karyopharm Therapeutics Inc. | 1 | $1,550 |
| Janssen Scientific Affairs, LLC | 2 | $586 |
| Boston Scientific | 5 | $161 |
| AbbVie | 1 | $118 |
| Gilead | 1 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $63 |
| AstraZeneca | 1 | $60 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$63,885 in reported general payments places this provider in the 85th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 111 | $1,970,880 |
| Lenalidomide | 132 | $1,795,595 |
| PomalystPomalidomide | 73 | $1,572,435 |
| NinlaroIxazomib Citrate | 14 | $180,680 |
| Atovaquone | 13 | $3,582 |
| Acyclovir | 146 | $1,777 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $308 |
| Prochlorperazine Maleate | 13 | $204 |
| Dexamethasone | 14 | $186 |
| Tramadol Hcl | 22 | $167 |
| Oxycodone Hcl | 22 | $102 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 13 | $100 |
| Lorazepam | 11 | $17 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $19,122 | $1,970,880111 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $3,095 | $180,68014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 79 hematology providers in Florida.
Other hematology in Tampa
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Doris HansenTampa$141K
- Alan ListTampa$49K
- Michael JainTampa$48K
- Lubomir SokolTampa$19K
- Kamran DarabiTampa$6K
- Lia PerezTampa$3K
- Nima GhalehsariTampa$3K
- Elizabeth SagatysTampa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.